Finding the perfect match between nanoparticles and microfluidics to respond to cancer challenges.,Nanomedicine: Nanotechnology, Biology and Medicine

当前位置： X-MOL 学术 › Nanomed. Nanotech. Biol. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Finding the perfect match between nanoparticles and microfluidics to respond to cancer challenges.
Nanomedicine: Nanotechnology, Biology and Medicine ( IF 4.2 ) Pub Date : 2019-12-13 , DOI: 10.1016/j.nano.2019.102139
F Raquel Maia ₁ , Rui L Reis ₁ , Joaquim M Oliveira ₁

Affiliation

The clinical translation of new cancer theranostic has been delayed by inherent cancer's heterogeneity. Additionally, this delay has been enhanced by the lack of an appropriate in vitro model, capable to produce accurate data. Nanoparticles and microfluidic devices have been used to obtain new and more efficient strategies to tackle cancer challenges. On one hand, nanoparticles-based therapeutics can be modified to target specific cells, and/or molecules, and/or modified with drugs, releasing them over time. On the other hand, microfluidic devices allow the exhibition of physiologically complex systems, incorporation of controlled flow, and control of the chemical environment. Herein, we review the use of nanoparticles and microfluidic devices to address different cancer challenges, such as detection of CTCs and biomarkers, point-of-care devices for early diagnosis and improvement of therapies. The future perspectives of cancer challenges are also addressed herein.

中文翻译：

寻找纳米颗粒和微流体之间的完美匹配，以应对癌症挑战。

由于固有的癌症异质性，新的肿瘤治疗药物的临床翻译被推迟了。此外，由于缺乏能够生成准确数据的合适的体外模型，这种延迟也有所增加。纳米颗粒和微流体装置已被用于获得新的和更有效的策略来应对癌症挑战。一方面，可以修饰基于纳米颗粒的治疗剂以靶向特定的细胞和/或分子，和/或用药物修饰，从而随时间释放它们。另一方面，微流体装置允许展示生理上复杂的系统，并入受控流以及控制化学环境。在此，我们回顾了使用纳米颗粒和微流控设备来应对不同的癌症挑战，例如CTC和生物标志物的检测，用于早期诊断和治疗改进的即时医疗设备。本文还讨论了癌症挑战的未来观点。

更新日期：2019-12-17

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文